Jazz Pharmaceuticals: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q3 earnings, missing estimated earnings by 1.43% with an EPS of $4.84 versus an estimate of $4.91. However, revenue was up $31.49 million from the same period last year. Last quarter, the company beat the EPS estimate which was followed by a 1.64% increase in the share price the next day.
November 08, 2023 | 9:25 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Jazz Pharmaceuticals missed Q3 earnings estimates but saw a YoY revenue increase. Last quarter's EPS beat led to a share price increase.
Jazz Pharmaceuticals missed its Q3 earnings estimates, which could negatively impact the stock. However, the company's revenue increased YoY, which is a positive sign. Additionally, the company's stock price increased after it beat EPS estimates last quarter, suggesting that the market may react positively to better-than-expected earnings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100